Remi Barbier has served as PTI's President and Chief Executive Officer since he founded the Company in 1998. Prior to PTI, Mr. Barbier helped in the growth or founding of: Exelixis Inc., a functional genomics company; ArQule, a chemistry company; and EnzyMed (now owned by Albany Molecular Research), a chemistry company. Prior to PTI Mr. Barbier served as Chief Operating Officer of Exelixis. Prior to that, he was Vice President of Corporate Development and Clinical Project Manager of Xoma Corporation, a biotechnology company. Mr. Barbier received his undergraduate degree from Oberlin College and his graduate degree from the University of Chicago.
Dr. Nadav Friedmann joined PTI as Chief Medical and Operating Officer in October 2001 and has served as a director since September 1998. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various leadership positions, with Johnson & Johnson, a healthcare company, including Vice President and Head of Research of J&J Biotechnology Center. Prior to that, Dr. Friedmann was Medical Director of Abbott Laboratories. Dr. Friedmann is a graduate of Albert Einstein College of Medicine, where he received an MD, and of the University of California, San Diego, where he received a PhD degree in Biochemistry.
Dr. Gussin has served as a director since March 2003. He worked at Johnson & Johnson (J&J) for 26 years, most recently as chief scientific officer and corporate vice president, science and technology from 1986 through 2000. Prior to assuming this role, Dr. Gussin worked at J&J's McNeil division for 12 years, most recently as vice president, research and development and vice president, scientific affairs. Over the years, Dr. Gussin has won numerous professional awards. In 1996 he received on behalf of J&J the National Medal of Technology awarded by the president of the United States. Dr. Gussin sits on the advisory boards of the Duquesne University Pharmacy School, The Graduate School of the University of Notre Dame, The Harvard University School of Public Health and the University of Michigan Medical School Department of Pharmacology.
Michael O'Donnell has served as a director since June 1998. Mr. O'Donnell is a member of the law firm of Wilson Sonsini Goodrich & Rosati, Professional Corporation, PTI's corporate counsel. Mr. O'Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life science companies. Mr. O'Donnell received a JD degree, cum laude, from Harvard University and a BA degree from Bucknell University, summa cum laude.
Saira Ramasastry has served as a director since February 2013. Prior to 2013, Ms. Ramasastry was an advisor to the Company. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a company she founded to provide strategic advice, business development solutions and innovative financing strategies for life science companies. From 1999 to 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. From 1997 to 1998, she was a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Biosciences, Inc. and Repros Therapeutics Inc., both publicly-held biopharmaceutical companies, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the Board of Directors of the American Liver Foundation. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as an M. Phil. in Management Studies from the University of Cambridge.
Sanford Robertson has served as a director since September 1998. Mr. Robertson is a general partner of Francisco Partners, a technology investment fund. He is the founder and former chairman of Robertson, Stephens & Company, an investment banking firm. Mr. Robertson is also the founder of Robertson, Colman, Siebel & Weisel, later renamed Montgomery Securities. He is also a former director of AIM Management Group Inc. (now AMVESCAP) and BankAmerica Corporation. Mr. Robertson received his BBA and MBA degrees with distinction from the University of Michigan.
Dr. Pat Scannon is Chief Biotechnology Officer, Executive Vice President and a member of the Board of XOMA Ltd., a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibody and other therapeutic proteins. Under Dr. Scannon's technical leadership, XOMA has identified, developed, tested and scaled-up numerous monoclonal antibodies. A Board-certified internist, Dr. Scannon is also a member of the American College of Physicians. He is also currently a member of the Defense Sciences Research Council, an advisory board for the Defense Advanced Research Projects Agency and a member of the Department of Defense's Threat Reduction Advisory Committee, where he is Chair of the ChemBioWarfare Defense Panel. Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and a medical degree from the Medical College of Georgia.